All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo product controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 for on were presented irratable by Dr. O''Connor to the FDA. The FDA panel acknowledged bowel and syndrom the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative product and for drop in symptoms irratable was demonstrated. In 1992, Belen Anibarro, MD, studied bowel five children with asthma with syndrom and product metabisulfite intolerance for confirmed by oral challenge testing. The test was repeated after premedication irratable with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

In 1990 study in San Diego, CA the 5 active bowel subjects with allergic rhinitis had a lowered total serum IgE from Day 0 to Day 90 while 4 placebo subjects, (2 with allergic rhinitis, 1 with asthma and 1 with both), had flat or increased IgE levels.4 In a randomized, double-blind, placebo controlled study of symptoms and serum IgE levels in San Diego, CA in mid-1991, subjects had syndrom and product allergic rhinitis and/or asthma. Serum was drawn at Day 0 and Day 30. Seven of the 10 active treated subjects had a reduction for in total serum IgE levels. In 10 placebo treated subjects, 5 had levels of total irratable serum bowel and syndrom IgE that stayed product the same (plus or minus 5%), 3 decreased and 2 increased.5 Statistical analysis of the open-label for study as well as the double-blind irratable and bowel randomized placebo controlled study have shown a significant effect of syndrom vitamin B12 in lowering serum IgE concentrations.